7:31 am Merck: FDA approves ZONTIVITY (vorapaxar) for the reduction of thrombotic cardiovascular events in patients with a history of heart attack or with peripheral arterial disease
View todays social media effects on MRK
View the latest stocks trending across Twitter. Click to view dashboard
See who Merck is hiring next, click here to view
